Background: The kidney is one major organ affected by cancer and its associated therapies. The aim of this study was to compare the levels of depression, quality of life and sleep quality in hemodialysis patients with or without cancer, and to analyze the associations with the malnutrition-inflammation score (MIS). Patients and Methods: In this cross-sectional study, 40 cancer patients under hemodialysis and 44 patients under hemodialysis without cancer who served as the control group were included. Participants underwent structured interviews to investigate depression, quality of life, sleep quality and restless legs syndrome. Results: Hemodialysis patients with cancer had a greater depression score (16.5 ± 4.8 vs. 10.8 ± 5.2, p < 0.001). Patients had similar physical and mental composite quality of life scores. Patients under hemodialysis with cancer had poor quality of sleep (mean score 8.8 ± 3.5 vs. 6.4 ± 4.1, p = 0.011) and a higher prevalence of restless leg syndrome (55.9 vs. 25.7%, p = 0.011). These features were associated with MIS in patients without cancer but not in patients with cancer. Conclusion: Cancer patients undergoing hemodialysis present a higher prevalence of depression, poor quality of life, sleep disorders; however, associations of these features with MIS are different in hemodialysis patients with or without cancer. These findings can change the clinical approach to these patients.

1.
Parahyba MI, Simoes CCS: Disability prevalence among the elderly in Brazil. Ciênc Saúde Colet 2006;11:967-974.
2.
Lopes LF, Camargo B, Bianchi A: Os efeitos tardios do tratamento do câncer infantil. Rev Assoc Med Bras 2000;46:277-284.
3.
Tonbul HZ, Demir M, Altintepe L, Guney I, Yeter E, Turk S, Yeksan M, Yildiz A: Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Ren Fail 2006;28:287-294.
4.
Pecoits-Filho R, Stevinkel P, Lindholm B, Bergstrom J, Noronha I, Abensur H: Malnutrition, inflammation, and atherosclerosis (MIA syndrome) in chronic renal failure patients. J Bras Nefrol 2002;24:236-246.
5.
Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507-1519.
6.
Mauricio SF, Da Silva JB, Bering T, Correia MI: Relationship between nutritional status and the Glasgow prognostic score in patients with colorectal cancer. Nutrition 2013;29:625-629.
7.
Iliescu EA, Coo H, McMurray MH, Meers CL, Quinn MM, Singer MA, Hopman WM: Quality of sleep and health-related quality of life in haemodialysis patients. Nephrol Dial Transplant 2003;18:126-132.
8.
Li ZJ, Na X, Mao HP, Wei X, Chen JH, Yang X, Zhou SF, Li ZB, Yu XQ: Association between depression and malnutrition-inflammation complex syndrome in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol 2011;43:875-882.
9.
Ujszaszi A, Czira ME, Fornadi K, Novak M, Mucsi I, Molnar MZ: Quality of life and protein-energy wasting in kidney transplant recipientes. Int Urol Nephrol 2012;44:1257-1268.
10.
Riella MC: Nutritional evaluation of patients receiving dialysis for the management of protein-energy wasting: what is old and what is new? J Ren Nutr 2013;23:195-198.
11.
He T, Na X, Mao HP, Wei X, Chen JH, Guo N, et al: Malnutrition-inflammation score predicts long-term mortality in Chinese PD patients. Clin Nephrol 2013;79:477-483.
12.
Kamyar KZ, Joel DK, Michael HH, Gladys B: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507-1519.
13.
Araujo SM, de Bruin VM, Nepomuceno LA, Maximo ML, Daher Ede F, Correia Ferrer DP, de Bruin PF: Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med 2010;11:785-790.
14.
Ware JE, Kosinski M, Keller SD: SF-36 physical and mental health summary scales: a user's manual. Boston, New England Medical Center - The Health Institute, 1994.
15.
Thase MC, Hersen M, Bellack A, Himmehoch JM, Kupper DJ: Validation of a Hamilton subscale for endogenomorphic depression. J Affect Disord 1983;5:267-276.
16.
Walters AS: Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-642.
17.
Masuko AH, Carvalho LBC, Machado MAC, Morais JF, Prado LBF, Prado GF: Translation and validation into the Brazilian Portuguese of the restless legs syndrome rating scale of the International Restless Legs Syndrome Study Group. Arq Neuropsiquiatr 2008;66:832-836.
18.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr Res 1989;28:193-213.
19.
Ramirez SP, Macedo DS, Sales PMG, Figueiredo SM, Daher EF, Araujo SM, Pargament KI, Hyphantis TN, Carvalho AF: The relationship between religious coping, psychological distress and quality of life in hemodialysis patients. J Psychosom Res 2012;72:129-135.
20.
Li J, Guo Q, Ye X, Lin J, Yi C, Mao H, Yang X, Yu X: Prevalence and risk factors of sleep disturbance in continuous ambulatory peritoneal dialysis patients in Guangzhou, southern China. Int Urol Nephrol 2012;44:929-936.
21.
Ibrahim S, El Salamony O: Depression, quality of life and malnutrition-inflammation scores in hemodialysis patients. Am J Nephrol 2008;28:784-791.
22.
Razeghi E, Sahraian MA, Heidari R, Bagherzadeh M: Association of inflammatory biomarkers with sleep disorders in hemodialysis patients. Acta Neurol Belg 2012;112:45-49.
23.
La Manna G, Pizza F, Persici E, Baraldi O, Comai G, Cappuccilli ML, Centofanti F, Carretta E, Plazzi G, Colì L, Montagna P, Stefoni S: Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 2011;26:1976-1983.
24.
Sánchez-Lara K, Turcott JG, Juárez E, Guevara P, Núñez-Vakencia C, Oñate-Ocaña LF, Flores D, Arieta O: Association of nutritional parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advances non-small-cell lung cancer: a prospective study. Nutr Cancer 2012;64:526-534.
25.
Dessi M, Noce A, Agnoli A, De Aangelis S, Fuiano L, Tozzo C, Taccone-Gallucci M, Fuiano G, Federici G: The usefulness of the prognostic inflammatory and nutritional index (PINI) in a haemodialysis population. Nutr Metab Cardiovasc Dis 2009;19:811-815.
26.
Demir M, Kucuk A, Sezer MT, Aaltuntas A, Kaya S: Malnutrition-inflammation score and endothelial dysfunction in hemodialysis patients. J Ren Nutr 2010;20:377-383.
27.
Neto JFR, Ferraz MB, Cendoroglo M, Draibe S, Yu L, Sesso R: Quality of life at the initiation of maintenance dialysis treatment - a comparison between the SF-36 and the KDQ questionnaires. Qual Life Res 2000;9:101-107.
28.
Santos PR, Daher EF, Silva GB Jr, Liborio AB, Kerr LR: Quality of life assessment among hemodialysis patients in a single centre: a 2-year follow-up. Qual Life Res 2009;18:S41-S46.
29.
Ferreira RC, Silva Filho CR: Quality of life of chronic renal patients on hemodialysis in Marília, SP, Brazil. J Bras Nefrol 2011;33:129-135.
30.
Kusleikaite N, Bumblyte IA, Kuzminskis V, Vaiciuniene R: The association between health-related quality of life and mortality among hemodialysis patients. Medicina (Kaunas) 2010;46:531-537.
31.
Santos PR, Kerr Pontes LRS: Mudança do nível de qualidade de vida em portadores de insuficiência renal crônica terminal durante seguimento de 12 meses. Rev Assoc Med Bras 2007;53:329-334.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.